<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949985</url>
  </required_header>
  <id_info>
    <org_study_id>2018-00448</org_study_id>
    <nct_id>NCT03949985</nct_id>
  </id_info>
  <brief_title>Longitudinal Hemostatic Profile After Stopping Estroprogestative Contraceptives</brief_title>
  <acronym>PILL-OFF</acronym>
  <official_title>Longitudinal Hemostatic Profile After Stopping Estroprogestative Contraceptives: a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective cohort evaluates the longitudinal profile of hemostatic biomarkers during
      the first 3 months after having stopped a combined oral contraceptive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women using a combined oral contraceptive (COC) and who have decided to stop it or switch it
      to a non-estrogenic contraceptive are included. At baseline, before the COC is stopped, and
      at multiple time points during the 3 months of follow-up, blood will be drawn to evaluate the
      hemostatic profile. Findings are compared with a control group of women without an estrogenic
      contraceptive, who are also followed for 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in normalized APC sensitivity ratio</measure>
    <time_frame>Three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Endogenous Thrombin Potential (Thrombin Generation Assay)</measure>
    <time_frame>Three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentrations of sex hormone-binding globulin</measure>
    <time_frame>Three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fibrinolysis assay</measure>
    <time_frame>Three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in individual coagulation factors</measure>
    <time_frame>Three months</time_frame>
    <description>The following coagulation factors will be assessed: fibrinogen, protein C, protein S, antithrombin, factor VIII</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contraception-related satisfaction</measure>
    <time_frame>Three months</time_frame>
    <description>Satisfaction will be estimated by the use of the Ortho Birth Control Satisfaction Assessment Tool questionnaire.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Estrogenic contraceptive users</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-estrogenic contraceptive users</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tests of biological hemostatic profile associated with contraceptives</intervention_name>
    <description>Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)</description>
    <arm_group_label>Estrogenic contraceptive users</arm_group_label>
    <arm_group_label>Non-estrogenic contraceptive users</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women aged 18-50 years who are current users of estrogenic contraceptives and have decided
        to stop it or replace it with a non-estrogenic contraceptive.

        Women aged 18-50 years who are not current users of estrogenic contraceptives.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women

          -  18-50 years

          -  current use (for at least 3 months) of an estrogenic contraceptive with the decision
             to stop it or replace it with a non-estrogenic contraceptive (estrogen group)

          -  no current use of an estrogenic contraceptive (control group)

        Exclusion Criteria:

          -  personal history of VTE

          -  known thrombophilia

          -  recent medical event (hospitalization, surgery, cancer)

          -  pregnancy, post-partum period, current breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Geneva University Hospitals</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Blondon</last_name>
      <phone>+41.22.372.92.92</phone>
      <email>marc.blondon@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Justine Hugon-Rodin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Marc Blondon</investigator_full_name>
    <investigator_title>Co-Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

